Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer

Advances in Therapy

Volumn 25, Issue 10, 2008, Pages 1075-1084

  Ucar, Edip ^a   Semerci, Ersan ^a   Ustun, Hasan ^b   Yetim, Tugba ^a   Huzmeli, Can ^a   Gullu, Murat ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alfa fetoprotein; CA 19 9; CA 72 4; Carcinoembryonic antigen; Gastric cancer

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 61749094899     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0100-4     Document Type: Article

References (27)

1. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol. 2002;12:111-127. (Pubitemid 34522348)
2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075-1107. (Pubitemid 27310783)
3. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA 72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105-110. (Pubitemid 32591564)
4. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;96:14-18. (Pubitemid 47015443)
5. Duraker N, Celik AN. The prognostic significance of preoperative serum CA 19-9 in patients with respectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001;76:266-271. (Pubitemid 32381683)
6. Choi SR, Jang JS, Lee JH, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51:2081-2086. (Pubitemid 44832595)
7. Yamashita K, Sakuramoto S, Kikuchi S, Katada N, Kobayashi N, Watanabe M. Surgical resection of stage IV gastric cancer and prognosis. Anticancer Res. 2007;27:4381-4386.
8. Gonzalez A, Vizoso F, Allende MT, Sanchez MT, Balibrea JL, Ruibal A. Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers. 1996;11:165-171. (Pubitemid 26373598)
9. Tocchi A, Costa G, Lepre L, et al. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol. 1998;124:450-455. (Pubitemid 28407579)
10. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
11. Japanese Gastric Cancer Association. Japanese classification of gastric cancer-2nd English edition. Gastric Cancer. 1998;1:10-24.
12. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumor Biol. 2001;22:318-322. (Pubitemid 32823950)
13. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer. 1995;75:451-456.
14. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22:2311-2316. (Pubitemid 34857058)
15. Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL. A carbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 1991;266:14869-14872. (Pubitemid 21907587)
16. Lai IR, Lee WJ, Huang MT, et al. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology. 2002;49:1157-1160.
17. Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:89-92.
18. Byrne DJ, Browning MC, Cuschieri A. CA72-4: a new tumor marker for gastric cancer. Br J Surg. 1990;77:1010-1013. (Pubitemid 20273525)
19. Kodama I, Koufuji K, Kawabata S, et al. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg. 1995;80:45-48.
20. Bates SE, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol. 1987;14:102-138. (Pubitemid 17134607)
21. Libman E, Lemberger J, Kollin J. Alphafetoprotein in the serum of patients with primary gastric cancer and liver metastases. Acta Hepatogastroenterol. 1979;26:198-202. (Pubitemid 9194957)
22. Chang YC, Nagasue N, Kohno H, et al. Clinicopathologic features and long-term results of α-fetoprotein-producing gastric cancer. Am J Gastroenterol. 1990;85:1480-1485.
23. Kono K, Amemiya H, Sekikawa T, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg. 2002;19:359-365. (Pubitemid 35356727)
24. Webb A, Scott-Mackie P, Cunningham D, et al. The prognostic value of serum and immunohistochemical tumor markers in advanced gastric cancer. Eur J Cancer. 1996;32:63-68.
25. Nakajima K, Takenori O, Suzuki T, et al. Impact of preoperative serum carcinoembryonic antigen, CA 19-9 and alpha-fetoprotein levels in gastric cancer patients. Tumor Biol. 1998;19:464-469. (Pubitemid 28539328)
26. Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 1999;57:55-62. (Pubitemid 29308672)
27. Nakamura T, Tabuchi Y, Nakae S, Ohno M, Saitoh Y. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival. Cancer. 1996;77:1741-1746. (Pubitemid 26111862)